Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMH4ANG)

Drug Name

HMN-214 Drug Info

Synonyms

N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic cancer	2C10	Discontinued in Phase 1	[1]
Prostate cancer	2C82.0	Discontinued in Phase 1	[1]

Therapeutic Class

Anticancer Agents

Cross-matching ID

PubChem CID: 9888590
ChEBI ID: CHEBI:91440
CAS Number: CAS 173529-46-9
TTD Drug ID: DMH4ANG

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Polo-like kinase 1 (PLK1)	TTIYVQP	PLK1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Polo-like kinase 1 (PLK1)	DTT	PLK1	4.492	5.573	4.555	2.459

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Pancreatic cancer

ICD Disease Classification

2C10

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Polo-like kinase 1 (PLK1)	DTT	PLK1	4.16E-07	-0.38	-0.72

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010558)
2	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.